DE69634416T2 - Chinolin-derivate - Google Patents

Chinolin-derivate Download PDF

Info

Publication number
DE69634416T2
DE69634416T2 DE69634416T DE69634416T DE69634416T2 DE 69634416 T2 DE69634416 T2 DE 69634416T2 DE 69634416 T DE69634416 T DE 69634416T DE 69634416 T DE69634416 T DE 69634416T DE 69634416 T2 DE69634416 T2 DE 69634416T2
Authority
DE
Germany
Prior art keywords
compound
formula
pharmaceutically acceptable
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634416T
Other languages
German (de)
English (en)
Other versions
DE69634416D1 (de
Inventor
Giuseppe Arnaldo Maria Giardina
Mario Grugni
Luca Francesco Raveglia
Carlo Farino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI952461 external-priority patent/IT1276170B1/it
Priority claimed from ITMI961689 external-priority patent/IT1307331B1/it
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of DE69634416D1 publication Critical patent/DE69634416D1/de
Publication of DE69634416T2 publication Critical patent/DE69634416T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69634416T 1995-11-24 1996-11-22 Chinolin-derivate Expired - Fee Related DE69634416T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI952461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
ITMI952461 1995-11-24
ITMI961689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici
ITMI961689 1996-08-02
PCT/EP1996/005203 WO1997021680A1 (en) 1995-11-24 1996-11-22 Quinoline derivatives

Publications (2)

Publication Number Publication Date
DE69634416D1 DE69634416D1 (de) 2005-04-07
DE69634416T2 true DE69634416T2 (de) 2005-12-29

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634416T Expired - Fee Related DE69634416T2 (de) 1995-11-24 1996-11-22 Chinolin-derivate

Country Status (26)

Country Link
US (1) US6277862B1 (enExample)
EP (1) EP0876347B1 (enExample)
JP (1) JP2000501104A (enExample)
KR (1) KR19990071597A (enExample)
CN (1) CN1207730A (enExample)
AP (1) AP9801237A0 (enExample)
AR (1) AR004972A1 (enExample)
AT (1) ATE289994T1 (enExample)
BG (1) BG102558A (enExample)
BR (1) BR9611820A (enExample)
CA (1) CA2238298A1 (enExample)
CZ (1) CZ157998A3 (enExample)
DE (1) DE69634416T2 (enExample)
EA (1) EA002124B1 (enExample)
ES (1) ES2236757T3 (enExample)
IL (1) IL124522A0 (enExample)
MX (1) MX9804107A (enExample)
NO (1) NO311212B1 (enExample)
NZ (1) NZ323387A (enExample)
OA (1) OA11010A (enExample)
PL (1) PL326967A1 (enExample)
SK (1) SK66798A3 (enExample)
TR (1) TR199800924T2 (enExample)
TW (1) TW353066B (enExample)
UY (1) UY24733A1 (enExample)
WO (1) WO1997021680A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170837B1 (pl) 1991-10-18 1997-01-31 Monsanto Co S rod ek g r zybobó j c zy PL PL PL PL PL PL
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2000058313A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US20040152726A1 (en) * 2001-04-11 2004-08-05 Carlo Farina Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303086D0 (en) * 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
BRPI0517567A (pt) * 2004-11-09 2008-06-17 Smithkline Beecham Corp composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504641A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
JP2010540553A (ja) * 2007-09-28 2010-12-24 グラクソスミスクライン エルエルシー グリコーゲンホスホリラーゼ阻害剤化合物及びその医薬組成物
MX2010003440A (es) * 2007-09-28 2010-04-21 Glaxosmithkline Llc Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS6399057A (ja) * 1986-06-27 1988-04-30 Nippon Shinyaku Co Ltd グリシン誘導体
RO114445B1 (ro) * 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
EP0876347B1 (en) 2005-03-02
EA199800477A1 (ru) 1998-12-24
AP9801237A0 (en) 1998-06-30
AR004972A1 (es) 1999-04-07
US6277862B1 (en) 2001-08-21
OA11010A (en) 2003-03-06
JP2000501104A (ja) 2000-02-02
ES2236757T3 (es) 2005-07-16
NZ323387A (en) 2000-02-28
CZ157998A3 (cs) 1998-12-16
NO311212B1 (no) 2001-10-29
TW353066B (en) 1999-02-21
NO982331L (no) 1998-07-22
MX9804107A (es) 1998-09-30
CN1207730A (zh) 1999-02-10
ATE289994T1 (de) 2005-03-15
EA002124B1 (ru) 2001-12-24
SK66798A3 (en) 1999-01-11
TR199800924T2 (xx) 1998-08-21
WO1997021680A1 (en) 1997-06-19
UY24733A1 (es) 2001-08-27
PL326967A1 (en) 1998-11-09
DE69634416D1 (de) 2005-04-07
CA2238298A1 (en) 1997-06-19
BG102558A (bg) 1999-03-31
KR19990071597A (ko) 1999-09-27
BR9611820A (pt) 1999-07-13
EP0876347A1 (en) 1998-11-11
NO982331D0 (no) 1998-05-22
IL124522A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
DE69628334T2 (de) Chinolin derivate als nk3 antagoniste
DE69533408T2 (de) Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
US6277862B1 (en) Quinoline derivatives
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
DE69816290T2 (de) Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
DE3877406T2 (de) Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung.
DE602004005016T2 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
WO1997021680A9 (en) Quinoline derivatives
DE2011806C3 (de) Tricyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE60209362T2 (de) 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
DE69626416T2 (de) Salze von chinolinderivaten als nk3 antagonisten
JPH08169884A (ja) シクロプロパクロメンカルボン酸誘導体
DE69934514T2 (de) Chinolinderivate als nk-2 und nk-3 rezeptor-liganden
DE68905845T2 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
DE602005004039T2 (de) Nicht-peptidische bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus
DE69824582T2 (de) Neuartige Chinolin- und Naphthalincarboxamide, pharmazeutische Zusammensetzungen und Verfahren zum Inhibieren von Calpain
DE60015732T2 (de) Amidverbindungen zur stärkung der cholinergischen wirkung
DE69920516T2 (de) Substituierte oxime und hydrazone als neurokinin antagonisten
DE3813531A1 (de) Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
EP1335720A1 (de) Sulfonamiden zur behandlung von erkrankungen des zentralen nervensystems
DE69826881T2 (de) Neue indolcarboxamide, pharmazeutische zusammensetzungen und methoden zur hemmung von calpain
DE69210229T2 (de) Dihydrochinolin NMDA Antagonisten
WO2012001438A1 (en) Use of kynurenic acid amide derivatives for the treatment of huntington's disease
DE2819215C2 (enExample)
AU757836B2 (en) Quinoline derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee